{"id":"fenofibrate-rosuvastatin","safety":{"commonSideEffects":[{"rate":null,"effect":"Myalgia or muscle pain"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Rhabdomyolysis (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fenofibrate is a fibrate that acts as a peroxisome proliferator-activated receptor alpha (PPAR-α) agonist, increasing lipolysis and reducing triglyceride-rich lipoprotein production while raising HDL cholesterol. Rosuvastatin is a statin that competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels. Together, this combination addresses multiple lipid abnormalities in dyslipidemia.","oneSentence":"Fenofibrate activates PPAR-alpha to reduce triglycerides and increase HDL, while rosuvastatin inhibits HMG-CoA reductase to lower LDL cholesterol.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:32:47.645Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dyslipidemia with elevated triglycerides and LDL cholesterol"},{"name":"Cardiovascular risk reduction in patients with mixed dyslipidemia"}]},"trialDetails":[{"nctId":"NCT03510884","phase":"PHASE3","title":"An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-05-31","conditions":"Hypercholesterolaemia","enrollment":153},{"nctId":"NCT01047501","phase":"PHASE3","title":"Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":702},{"nctId":"NCT01047683","phase":"PHASE3","title":"Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":229},{"nctId":"NCT01492361","phase":"PHASE3","title":"A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2011-11","conditions":"Cardiovascular Diseases","enrollment":8179},{"nctId":"NCT03510715","phase":"PHASE3","title":"An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-08-31","conditions":"Hypercholesterolemia","enrollment":18},{"nctId":"NCT02984982","phase":"PHASE4","title":"Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-11-15","conditions":"Hypercholesterolemia, Acute Coronary Syndrome","enrollment":206},{"nctId":"NCT02232360","phase":"PHASE4","title":"Effects of Combined Therapy With Statin Plus Fenofibrate on Coronary Atherosclerotic Plaque Compared With Statin Alone","status":"UNKNOWN","sponsor":"Gachon University Gil Medical Center","startDate":"2014-01","conditions":"Coronary Artery Disease","enrollment":106},{"nctId":"NCT03874260","phase":"PHASE4","title":"Cinical Trial to Explore the Efficacy of Statin/Choline Fenofibrate Combination Therapy vs Statin Monotherapy in Patients With Inadequately Controlled TG Despite Receiving Statin Monotherapy","status":"UNKNOWN","sponsor":"Daewon Pharmaceutical Co., Ltd.","startDate":"2018-07-25","conditions":"Dyslipidemias","enrollment":180},{"nctId":"NCT02262143","phase":"PHASE3","title":"Phase III Study of Rosuvastatin and Fenofibrate Versus Rosuvastatin in Mixed Dyslipidemia","status":"COMPLETED","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2014-11","conditions":"Mixed Dyslipidemias","enrollment":362},{"nctId":"NCT00923676","phase":"PHASE4","title":"Treatment of Hyperlipidemia and Sexual Dysfunction","status":"UNKNOWN","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2008-04","conditions":"Sexual Dysfunction, Hyperlipidemia","enrollment":300},{"nctId":"NCT00965315","phase":"","title":"A Multicenter Randomized Parallel-group Study to Investigate the Efficacy of a Combination of Rosuvastatin and Fenofibrate in the Patients With Diabetes or Atherosclerotic Vascular Diseases With Metabolic Syndrome","status":"AVAILABLE","sponsor":"National Taiwan University Hospital","startDate":"","conditions":"Diabetes, CVD","enrollment":""},{"nctId":"NCT00934258","phase":"","title":"Effect of Genes on Rosuvastatin Therapy for Hyperlipidemia","status":"AVAILABLE","sponsor":"National Taiwan University Hospital","startDate":"","conditions":"Hyperlipidemia","enrollment":""},{"nctId":"NCT00487136","phase":"PHASE1","title":"Interaction Between ABT-335, Rosuvastatin and Warfarin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-06","conditions":"Healthy","enrollment":45},{"nctId":"NCT00251680","phase":"PHASE3","title":"Efficacy of Lapaquistat Acetate in Subjects Currently Treated With Lipid-Lowering Therapy.","status":"COMPLETED","sponsor":"Takeda","startDate":"2005-10","conditions":"Type 2 Diabetes","enrollment":400},{"nctId":"NCT01414803","phase":"PHASE4","title":"Tolerability and Efficacy of Rosuvastatin - Fenofibrate Combine Therapy in Korean Patients With Combined Hyperlipidemia","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2009-03","conditions":"Hyperlipidemia","enrollment":180},{"nctId":"NCT01010516","phase":"PHASE4","title":"Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia","status":"UNKNOWN","sponsor":"University of Ioannina","startDate":"2009-10","conditions":"Dyslipidemia","enrollment":120},{"nctId":"NCT00300430","phase":"PHASE3","title":"Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.","status":"COMPLETED","sponsor":"Abbott","startDate":"2006-09","conditions":"Dyslipidemia, Coronary Heart Disease, Mixed Dyslipidemia","enrollment":1911}],"_emaApprovals":[],"_faersSignals":[{"count":4,"reaction":"BLOOD CHOLESTEROL INCREASED"},{"count":3,"reaction":"BLOOD TRIGLYCERIDES INCREASED"},{"count":2,"reaction":"ASTHENIA"},{"count":2,"reaction":"BLOOD GLUCOSE INCREASED"},{"count":2,"reaction":"CHEST PAIN"},{"count":2,"reaction":"DYSPEPSIA"},{"count":2,"reaction":"GAMMA-GLUTAMYLTRANSFERASE INCREASED"},{"count":2,"reaction":"MALIGNANT NEOPLASM PROGRESSION"},{"count":2,"reaction":"OEDEMA PERIPHERAL"},{"count":2,"reaction":"VOMITING"}],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"fenofibrate + rosuvastatin","genericName":"fenofibrate + rosuvastatin","companyName":"University of Campania Luigi Vanvitelli","companyId":"university-of-campania-luigi-vanvitelli","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fenofibrate activates PPAR-alpha to reduce triglycerides and increase HDL, while rosuvastatin inhibits HMG-CoA reductase to lower LDL cholesterol. Used for Dyslipidemia with elevated triglycerides and LDL cholesterol, Cardiovascular risk reduction in patients with mixed dyslipidemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}